CD8A and neoplasm: Consequently, the ratio of CD8+ T cells to Tregs in tumor grafts treated with αNKG2A-N215 (12 μg) was significantly (P < 0.05) higher than that in tumor grafts treated with αNKG2A + N215 (Figure S9), which was consistent with the difference between these two treatments in their antitumor effect.